CA
OTLK icon

CoreCap Advisors’s Outlook Therapeutics OTLK Stock Holding History

CoreCap Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-62
Closed -$99 – 2911
2025
Q2 		$99 Sell
62
-1,641
-96% -$2.62K ﹤0.01% 2682
2025
Q1 		$2.08K Buy
+1,703
New +$2.99K ﹤0.01% 2342

Other funds holding OTLK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CoreCap Advisors's OTLK Position: Q3 2025 in Review

CoreCap Advisors sold out of Outlook Therapeutics (OTLK) in Q3 2025, closing a stake of 62 shares — an estimated $99 sold.

CoreCap Advisors first reported a position in OTLK in Q1 2025 and held it in 2 quarters. The position peaked at $2.08K in Q1 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q3 2025.

  • CoreCap Advisors reported no remaining Outlook Therapeutics position as of Q3 2025 after selling out during the quarter.
  • CoreCap Advisors sold 62 Outlook Therapeutics shares in Q3 2025, an estimated $99.
  • CoreCap Advisors first reported a position in Outlook Therapeutics in Q1 2025 and held it in 2 quarters.
  • CoreCap Advisors's Outlook Therapeutics position peaked at $2.08K in Q1 2025.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2025.

Based on CoreCap Advisors's 13F filing for Q3 2025, filed 22 Oct 2025.